Table 2. Effective hemostasis at 12 hours after andexanet administration.
| Patients with baseline antifactor Xa activity ≥40 ng/mL ( N = 28) | Patients with baseline antifactor Xa activity ≥75 ng/mL ( N = 20) | |||||
|---|---|---|---|---|---|---|
| Patients | Excellent or good hemostasis, n (%) | 95% CI (%) | Patients | Excellent or good hemostasis, n (%) | 95% CI (%) | |
| All | 28 | 22 (78.6) | 59.0–91.7 | 20 | 15 (75.0) | 50.9–91.3 |
| Patients with intracranial hemorrhage | 22 | 18 (81.8) | 59.7–94.8 | 16 | 13 (81.3) | 54.4–96.0 |
| Patients with intracerebral bleeding a | 17 | 13 (76.5) | 50.1–93.2 | 12 | 9 (75.0) | 42.8–94.5 |
Abbreviation: CI, confidence interval.
a
Patients with intracerebral bleeding are a subset of patients with intracranial hemorrhage.